Equity Capital Markets
Our Equity Capital Markets team is experienced in the successful execution of all categories of private and public equity offerings
By connecting growth-oriented companies with a network of high-quality investors, we deliver compelling results for issuers of a variety of products.
- SPAC IPO
- Confidentially Marketed Public Offering (CMPO)
- Registered Direct (RD)
- Private Placement
- At-the-Market Offering (ATM)
- Convertible Bond
- Other hybrid solutions
Our relationships are based on a detailed understanding of our clients’ objectives. Our approach brings together the full capabilities of Cowen to meet their needs. Our mission is to provide a high-touch experience and be a trusted resource for all of our clients, across all stages of growth.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company in the field of cellular metabolism and adjacent areas of biology, with the goal of making transformative medicines for the treatment of cancer and rare genetic diseases, or RGDs.
argenx SE is a clinical stage biotechnology company developing a deep pipeline of differentiated antibody based therapies for the treatment of severe autoimmune diseases and cancer.
Building on 30 years of experience in transfusion diagnostics, Quotient is a commercial stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced.
Grant MillerManaging Director and Head, Capital Markets Group646 562 1164
David BohnManaging Director, Equity Capital Markets646 562 1207
Michael CampbellManaging Director, Equity Capital Markets415 646 7262
Jason FentonManaging Director and Head, Healthcare Capital Markets
Bill FollisManaging Director, Equity Capital Markets646 562 1237
Iain FranksManaging Director and Head, Convertible and Equity-Linked Products415 646 7266
Michael MurphyManaging Director, Equity Capital Markets646 562 1171
Chris WeekesManaging Director, Equity Capital Markets646 562 1133
Eric KasperDirector, Equity Capital Markets646 562 1615